Hyperactive Ras in developmental disorders and cancer
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Ras genes are the most common targets for somatic gain-of-function mutations in human cancer. Recently, germline mutations that affect components of the Ras-Raf-mitogen-activated and extracellular-signal regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway were shown to cause several developmental disorders, including Noonan, Costello and cardio-facio-cutaneous syndromes. Many of these mutant alleles encode proteins with aberrant biochemical and functional properties. Here we will discuss the implications of germline mutations in the Ras-Raf-MEK-ERK pathway for understanding normal developmental processes and cancer pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NRAS or KRAS mutations are found in ;20-40% of myeloid malignancies and in 10-15% of acute lymphoblastic leukemia.4,5”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [4]
In the citing paper
“Approximately 55% of colorectal cancers (CRCs) are driven by mutational activation of KRAS, BRAF, NRAS, and thus are hard-wired to oncogenic RAS/RAF/MEK/ERK pathway signaling [1–3].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [1]
In the citing paper
“More than one-third of human tumors harbor activating RAS mutations2”
From Discovery and characterization of small molecules that target the GTPase Ral (2014) · cites this paper as [2]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“The finding that germline BRAF mutations underlie most cases of CFC syndrome is of exceptional interest to cancer biologists because, as discussed below, a V600E substitution in BRAF is one of the most common molecular lesions found in human cance”
BackgroundMassagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056 · cited 1×
“Akt is a kinase that promotes survival in many cell types by phosphorylating and therefore inactivating several pro-apoptotic proteins including BAD and Forkhead ( FKHR ) transcription factor”
BackgroundOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“The overexpression of oncogenic Ras in primary cells can induce senescence or growth arrest, unless accompanied by other genetic lesions such as loss of CDKN2A (also known as p16 INK4a ), CDKN2D (also known as p19 INK4d ) or TP53 (Ref”
Backgroundras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906 · cited 1×
“For example, in PC-12 rat adrenal phaeochromocytoma cells, the transient activation of Ras through epidermal growth factor ( EGF ) signalling stimulates proliferation, whereas nerve growth factor ( NGF )-dependent sustained activation of Ras induces differentiatio”
BackgroundThe GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392 · cited 1×
“jpg" NDATA ITEM> ]> Ras proteins are signal switch molecules that regulate cell fates by coupling receptor activation to downstream effector pathways that control diverse cellular responses including proliferation, differentiation and surviva”
BackgroundTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256 · cited 1×
“However, KRAS and NRAS escape functional inactivation by undergoing geranylgeranylation , which, as reviewed elsewher”
BackgroundMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808 · cited 1×
“However, one potential confounding issue in interpreting these studies is that the levels of oncogenic V600E BRAF kinase activity relative to wild-type BRAF that were measured in this report were substantially lower than levels that others have observe”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471 · cited 1×
“Use of tissue-specific Cre strains in the developing pancreas induced pancreatic cancer precursor lesions, and some animals developed invasive carcinomas with prolonged latency or in the presence of cooperating tumour-suppressor gene mutation”
Background
Research works printed but not linked: 1
- Roberts, A. et al. The cardio-facio-cutaneous (CFC) syndrome: a review. J. Med. Genet. (2006).
Cited by
Items 101–200 of 1,001
Regulatory Roles of MAPK Phosphatases in Cancer
Low, H. B., & Zhang, Y. (2016) · Immune Network · doi:10.4110/in.2016.16.2.85 · Cited by 205
Tartaglia, M., & Gelb, B. D. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05790.x · Cited by 198
Targeting Protein-Protein Interaction by Small Molecules
Jin, L., Wang, W., & Fang, G. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140028 · Cited by 195
NRAS Mutations Are Rare in Colorectal Cancer
Irahara, N., Baba, Y., Nosho, K., Shima, K., Yan, L., Dias-Santagata, D., Iafrate, A. J., Fuchs, C. S., Haigis, K. M., & Ogino, S. (2010) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e3181c93fd1 · Cited by 194
Requirement of the NF-κB Subunit p65/RelA for K-Ras–Induced Lung Tumorigenesis
Bassères, D. S., Ebbs, A., Levantini, E., & Baldwin, A. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4290 · Cited by 189
Jeong, W.-J., Yoon, J., Park, J.-C., Lee, S.-H., Lee, S.-H., Kaduwal, S., Kim, H., Yoon, J.-B., & Choi, K.-Y. (2012) · Science Signaling · doi:10.1126/scisignal.2002242 · Cited by 188
Next-generation sequencing identifies rare variants associated with Noonan syndrome
Chen, P.-C., Yin, J., Yu, H.-W., Yuan, T., Fernandez, M., Yung, C. K., Trinh, Q. M., Peltekova, V. D., Reid, J. G., Tworog-Dube, E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324128111 · Cited by 186
FOXM1 (Forkhead box M1) in Tumorigenesis
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00016-2 · Cited by 184
“…Mitsiades et al., 2004; Platanias, 2003; Pratilas and Solit, 2010; Pylayeva-Gupta et al., 2011; Roberts and Der, 2007; Sansal and Sellers, 2004; Schubbert et al., 2007; Sebolt-Leupold and Herrera, 2004; Steelman et al., 2004, 2011a,b; Vakiani and Solit, 2011;Yap et al., 2011;Yuan andCantley,…”
Chen, C., Liu, Y., Lu, C., Cross, J. R., Morris, J. P., Shroff, A. S., Ward, P. S., Bradner, J. E., Thompson, C., & Lowe, S. W. (2013) · Genes & Development · doi:10.1101/gad.226613.113 · Cited by 182
RAS-mediated oncogenic signaling pathways in human malignancies
Khan, A. Q., Kuttikrishnan, S., Siveen, K. S., Prabhu, K. S., Shanmugakonar, M., Al- Naemi, H. A., Haris, M., Dermime, S., & Uddin, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.001 · Cited by 179
Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer
Fois, S. S., Paliogiannis, P., Zinellu, A., Fois, A. G., Cossu, A., & Palmieri, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020612 · Cited by 180
Mitogen-activated protein kinases in hepatocellular carcinoma development
Min, L., He, B., & Hui, L. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.10.011 · Cited by 178
Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
Su, F., Bradley, W. D., Wang, Q., Yang, H., Xu, L., Higgins, B., Kolinsky, K., Packman, K., Kim, M. J., Trunzer, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1875 · Cited by 179
Self-citationNovel Allosteric Sites on Ras for Lead Generation
Grant, B. J., Lukman, S., Hocker, H. J., Sayyah, J., Brown, J. H., McCammon, J. A., & Gorfe, A. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025711 · Cited by 177
The Transcription Factor FOXM1 (Forkhead box M1)
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407173-5.00004-2 · Cited by 176
Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization
Lavoie, H., Thevakumaran, N., Gavory, G., Li, J. J., Padeganeh, A., Guiral, S., Duchaine, J., Mao, D. Y. L., Bouvier, M., Sicheri, F., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1257 · Cited by 174
Xavier, C. P. R., Lima, C. F., Preto, A., Seruca, R., Fernandes-Ferreira, M., & Pereira-Wilson, C. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.041 · Cited by 176
Zheng, Y., Xia, Y., Hawke, D., Halle, M., Tremblay, M. L., Gao, X., Zhou, X. Z., Aldape, K., Cobb, M. H., Xie, K., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.013 · Cited by 172
What We Have Learned About Pancreatic Cancer From Mouse Models
Pérez–Mancera, P. A., Guerra, C., Barbacid, M., & Tuveson, D. A. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.03.002 · Cited by 172
Function, regulation and pathological roles of the Gab/DOS docking proteins
Wöhrle, F. U., Daly, R. J., & Brummer, T. (2009) · Cell Communication and Signaling · doi:10.1186/1478-811x-7-22 · Cited by 171
Metabolic rewiring in melanoma
Ratnikov, B. I., Scott, D. A., Osterman, A. L., Smith, J. W., & Ronai, Z. A. (2017) · Oncogene · doi:10.1038/onc.2016.198 · Cited by 171
Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147
Gonsalves, W. I., Mahoney, M. R., Sargent, D. J., Nelson, G. D., Alberts, S. R., Sinicrope, F. A., Goldberg, R. M., Limburg, P. J., Thibodeau, S. N., Grothey, A., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju106 · Cited by 170
Colorectal Cancer: Molecular Mutations and Polymorphisms
Sameer, A. S. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00114 · Cited by 171
Thiazolidine-2,4-diones: Progress towards multifarious applications
Jain, V. S., Vora, D. K., & Ramaa, C. S. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.01.029 · Cited by 165
Knight, T., & Irving, J. A. E. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00160 · Cited by 164
Simi, L., Pratesi, N., Vignoli, M., Sestini, R., Cianchi, F., Valanzano, R., Nobili, S., Mini, E., Pazzagli, M., & Orlando, C. (2008) · American Journal of Clinical Pathology · doi:10.1309/lwdy1axhxuulnvhq · Cited by 164
Xavier, C. P. R., Lima, C. F., Fernandes-Ferreira, M., & Pereira-Wilson, C. (2009) · Nutrition and Cancer · doi:10.1080/01635580802710733 · Cited by 159
Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression
Drake, J. M., Graham, N. A., Stoyanova, T., Sedghi, A., Goldstein, A. S., Cai, H., Smith, D. A., Zhang, H., Komisopoulou, E., Huang, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120985109 · Cited by 159
Nan, X., Collisson, E. A., Lewis, S., Huang, J., Tamgüney, T. M., Liphardt, J. T., McCormick, F., Gray, J. W., & Chu, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318188110 · Cited by 158
“Abnormal activation of this pathway is a central event in many human cancers and results from activating mutations in BRAF itself or in upstream factors (such as the RAS genes) (3, 4).”
BackgroundGremer, L., Merbitz-Zahradnik, T., Dvorsky, R., Cirstea, I. C., Kratz, C. P., Zenker, M., Wittinghofer, A., & Ahmadian, M. R. (2011) · Human Mutation · doi:10.1002/humu.21377 · Cited by 158
Phosphoproteome dynamics reveal novel ERK1/2 MAP kinase substrates with broad spectrum of functions
Courcelles, M., Frémin, C., Voisin, L., Lemieux, S., Meloche, S., & Thibault, P. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.25 · Cited by 158
Wang, Y., Kim, E., Wang, X., Novitch, B. G., Yoshikawa, K., Chang, L.-S., & Zhu, Y. (2012) · Cell · doi:10.1016/j.cell.2012.06.034 · Cited by 151
Iacobuzio–Donahue, C. A. (2011) · Gut · doi:10.1136/gut.2010.236026 · Cited by 182
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
Sun, C., & Bernards, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.010 · Cited by 155
DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS
Lauth, M., Bergström, Å., Shimokawa, T., Tostar, U., Jin, Q., Fendrich, V., Guerra, C. E., Barbacid, M., & Toftgård, R. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1833 · Cited by 163
Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus
Li, Q., Haigis, K. M., McDaniel, A., Harding-Theobald, E. R., Kogan, S. C., Akagi, K., Wong, J. C. Y., Braun, B. S., Wolff, L., Jacks, T., et al. (2010) · Blood · doi:10.1182/blood-2010-04-280750 · Cited by 165
Self-citationA Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations
Riely, G. J., Johnson, M. L., Medina, C., Rizvi, N. A., Miller, V. A., Kris, M. G., Pietanza, M. C., Azzoli, C. G., Krug, L. M., Pao, W. J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318223c099 · Cited by 168
Étienne-Grimaldi, M.-C., Formento, J., Francoual, M., François, É., Formento, P., Renée, N., Laurent‐Puig, P., Chazal, M., Benchimol, D., Delpéro, J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4906 · Cited by 166
Discovery and characterization of small molecules that target the GTPase Ral
Yan, C., Liu, D., Li, L., Wempe, M. F., Guin, S., Khanna, M., Meier, J., Hoffman, B., Owens, C., Wysoczynski, C. L., et al. (2014) · Nature · doi:10.1038/nature13713 · Cited by 150
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras
Lauchle, J., Kim, D. S., Le, D., Akagi, K., Crone, M., Krisman, K., Warner, K., Bonifas, J. M., Li, Q., Coakley, K. M., et al. (2009) · Nature · doi:10.1038/nature08279 · Cited by 164
Self-citationParamasivam, M., Membrino, A., Cogoi, S., Fukuda, H., Nakagama, H., & Xodo, L. E. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp138 · Cited by 154
Mechanisms linking obesity and cancer
Louie, S. M., Roberts, L. S., & Nomura, D. K. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.02.008 · Cited by 147
Nishimura, T., Ishima, T., Iyo, M., & Hashimoto, K. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002558 · Cited by 154
Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis.
Hashimoto, Y., Akiyama, Y., Otsubo, T., Shimada, S., & Yuasa, Y. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq013 · Cited by 152
Flex, E., Jaiswal, M., Pantaleoni, F., Martinelli, S., Strullu, M., Fansa, E. K., Caye‐Eude, A., Luca, A. D., Lepri, F. R., Dvorský, R., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu148 · Cited by 166
KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy
Siddiqui, A. D., & Piperdi, B. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0811-z · Cited by 163
ER functions of oncogenes and tumor suppressors: Modulators of intracellular Ca2+ signaling
Bittremieux, M., Parys, J. B., Pinton, P., & Bultynck, G. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.01.002 · Cited by 150
“pathways, thereby controlling cell growth, differentiation and survival [178,179].”
BackgroundABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth
Remsberg, J. R., Suciu, R. M., Zambetti, N. A., Hanigan, T. W., Firestone, A. J., Sheth, A. I., Long, A. M., Ngo, N., Lum, K. M., Henry, C. L., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00785-8 · Cited by 148
Self-citationChen, X., Mitsutake, N., LaPerle, K., Akeno, N., ZANZONICO, P. B., Longo, V. A., Mitsutake, S., Kimura, E. T., Geiger, H., Santos, E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900343106 · Cited by 147
ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer
Ji, S., Qin, Y., Shi, S., Liu, X., Hu, H., Zhou, H., Gao, J., Zhang, B., Xu, W., Liu, J., et al. (2015) · Cell Research · doi:10.1038/cr.2015.30 · Cited by 137
Juvenile myelomonocytic leukaemia and Noonan syndrome
Strullu, M., Caye‐Eude, A., Lachenaud, J., Cassinat, B., Gazal, S., Fenneteau, O., Pouvreau, N., Pereira, S., Baumann, C., Contet, A., et al. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102611 · Cited by 153
Liao, W., Ye, Y., Zhang, N., Li, T., Wang, S., Cui, Y., Qi, L., Wu, P., Jiao, H., Xie, Y., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4309 · Cited by 142
Hole, P. S., Pearn, L., Tonks, A. J., James, P. E., Burnett, A. K., Darley, R. L., & Tonks, A. (2009) · Blood · doi:10.1182/blood-2009-06-222869 · Cited by 150
Sugiyama, M. G., Fairn, G. D., & Antonescu, C. N. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00070 · Cited by 153
“Ras Nanoclusters The Ras proteins (H-Ras, K-Ras, and N-Ras) are a family of small GTPases that are important downstream effectors of RTK signaling (Schubbert et al., 2007; Simanshu et al., 2017).”
BackgroundMicroRNA‐17∼92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways
Jin, H. Y., Oda, H., Lai, M., Skalsky, R. L., Bethel, K. J., Shepherd, J., Kang, S. G., Liu, W., Sabouri-Ghomi, M., Cullen, B. R., et al. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.178 · Cited by 146
“This places miR-17 B 92 in the pantheon of prominent cancer genes that includes Myc, Ras, Pik3ca (p110 a ), Pten, and p53 (Schubbert et al , 2007; Liu et al , 2009; Olivier et al , 2010; Dang, 2012).”
MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2
Wang, X., Shi, Z., Wang, X.-R., Cao, L., Wang, Y., Zhang, J., Yin, Y., Luo, H., Kang, C., Liu, N., et al. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1114-x · Cited by 138
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
Tomasini, P., Walia, P., Labbé, C., Jao, K., & Leighl, N. B. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0084 · Cited by 147
Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets
Knauf, J. A., & Fagin, J. A. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.013 · Cited by 143
Shi, Z., Chen, Q., Li, C.-Y., Wang, L., Qian, X., Jiang, C., Liu, X., Wang, X., Hai, L., Kang, C., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou084 · Cited by 137
Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer
Hutton, J. E., Wang, X., Zimmerman, L. J., Slebos, R. J. C., Trenary, I. A., Young, J. D., Li, M., & Liebler, D. C. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.058925 · Cited by 140
Chen, P., Wakimoto, H., Conner, D. A., Araki, T., Yuan, T., Roberts, A. E., Seidman, C. E., Bronson, R. T., Neel, B. G., Seidman, J. G., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43910 · Cited by 145
The GAP arginine finger movement into the catalytic site of Ras increases the activation entropy
Kötting, C., Kallenbach, A., Suveyzdis, Y., Wittinghofer, A., & Gerwert, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712095105 · Cited by 128
Molzan, M., Schumacher, B., Ottmann, C., Baljuls, A., Polzien, L., Weyand, M., Thiel, P., Rose, R., Rose, M., Kuhenne, P., et al. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01636-09 · Cited by 144
Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia
Emanuel, P. D. (2008) · Leukemia · doi:10.1038/leu.2008.162 · Cited by 128
Multifaceted role of Rho, Rac, Cdc42 and Ras in intercellular junctions, lessons from toxins
Popoff, M. R., & Geny, B. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2009.01.011 · Cited by 139
Transport proteins of the ABC family and multidrug resistance of tumor cells
Stavrovskaya, A. A., & Stromskaya, T. P. (2008) · Biochemistry (Moscow) · doi:10.1134/s0006297908050118 · Cited by 146
Malinowska-Ozdowy, K., Frech, C., Schönegger, A., Eckert, C., Cazzaniga, G., Stanulla, M., Stadt, U. Z., Mecklenbräuker, A., Schuster, M. K., Kneidinger, D., et al. (2015) · Leukemia · doi:10.1038/leu.2015.107 · Cited by 128
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1genes
Gelsi‐Boyer, V., Trouplin, V., Adélaïde, J., Aceto, N., Rémy, V., Pinson, S., Houdayer, C., Arnoulet, C., Sainty, D., Bentires‐Alj, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-299 · Cited by 147
Translational implications of somatic genomics in acute myeloid leukaemia
Meyer, S. C., & Levine, R. L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70008-7 · Cited by 149
Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
Yokota, T. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012799014968 · Cited by 138
Conserved Regulation of MAP Kinase Expression by PUF RNA-Binding Proteins
Lee, M., Hook, B. A., Pan, G., Kershner, A. M., Merritt, C., Seydoux, G., Thomson, J. A., Wickens, M., & Kimble, J. E. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030233 · Cited by 127
Genetic Approaches to Investigate the Role of CREB in Neuronal Plasticity and Memory
Barco, Á., & Marie, H. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8209-x · Cited by 145
MAP Kinases and Prostate Cancer
Rodríguez‐Berriguete, G., Fraile, B., Martínez-Onsurbe, P., Olmedilla, G., Paniagua, R., & Royuela, M. (2011) · Journal of Signal Transduction · doi:10.1155/2012/169170 · Cited by 154
Micro-RNA-155 is induced by K-Ras oncogenic signal and promotes ROS stress in pancreatic cancer
Wang, P., Zhu, C.-F., Ma, M.-Z., Chen, G., Song, M., Zeng, Z.-L., Lu, W.-H., Yang, J., Wen, S., Chiao, P. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4125 · Cited by 128
EGFR signaling and autophagy dependence for growth, survival, and therapy resistance
Jutten, B., & Rouschop, K. M. A. (2013) · Cell Cycle · doi:10.4161/cc.27518 · Cited by 125
Chan, G., Kalaitzidis, D., Usenko, T. S., Kutok, J. L., Yang, W., Mohi, G., & Neel, B. G. (2009) · Blood · doi:10.1182/blood-2008-10-182626 · Cited by 130
Fischer, M. M., Yen, W.-C., Kapoun, A. M., Wang, M., O’Young, G., Lewicki, J. A., Gurney, A. L., & Hoey, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2817 · Cited by 124
Mallette, F. A., & Richard, S. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.09.033 · Cited by 138
Heterogeneity and plasticity of epidermal stem cells
Schepeler, T., Page, M. E., & Jensen, K. B. (2014) · Development · doi:10.1242/dev.104588 · Cited by 119
“Members of the Ras family of small GTPases are activated downstream of most growth factor receptor pathways and are found to be mutated in a number of different cancers (Schubbert et al., 2007).”
Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis
Dennemärker, J., Lohmüller, T., Mayerle, J. V., Tacke, M., Lerch, M. M., Coussens, L. M., Peters, C., & Reinheckel, T. (2009) · Oncogene · doi:10.1038/onc.2009.466 · Cited by 120
SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype
Pasmant, É., Sabbagh, A., Hanna, N., Masliah‐Planchon, J., Jolly, E. R., Goussard, P., Ballerini, P. F., Cartault, F., Barbarot, S., Landman‐Parker, J., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.065243 · Cited by 118
Ashton‐Beaucage, D., Udell, C. M., Lavoie, H., Baril, C., Lefrançois, M., Chagnon, P., Gendron, P., Caron-Lizotte, O., Bonneil, É., Thibault, P., et al. (2010) · Cell · doi:10.1016/j.cell.2010.09.014 · Cited by 117
Cogoi, S., Shchekotikhin, A. E., & Xodo, L. E. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku574 · Cited by 115
Raf kinase inhibitory protein (RKIP): A physiological regulator and future therapeutic target
Zeng, L., Imamoto, A., & Rosner, M. R. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.10.1275 · Cited by 119
Pathomechanisms in schwannoma development and progression
Helbing, D. L., Schulz, A., & Morrison, H. (2020) · Oncogene · doi:10.1038/s41388-020-1374-5 · Cited by 122
Membrino, A., Cogoi, S., Pedersen, E. B., & Xodo, L. E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024421 · Cited by 132
Terrell, E. M., Durrant, D., Ritt, D. A., Sealover, N. E., Sheffels, E., Spencer-Smith, R., Esposito, D., Zhou, Y., Hancock, J. F., Kortum, R. L., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.004 · Cited by 113
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript tumorigenesis and Ras germline mutations contributing to a group of related developmental disorders known as the RASopathies (Fernández-Medarde and Santos, 2011; Schubbert et al., 2007).”
BackgroundItaliano, A., Hostein, I., Soubeyran, I., Fabas, T., Benchimol, D., Evrard, S., Gugenheim, J., Becouarn, Y., Brunet, R., Fonck, M., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0864-z · Cited by 114
Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study.
Dinu, D., Dobre, M., Panaitescu, E., Bîrlă, R., Iosif, C., Hoara, P. A., Caragui, A., Boeriu, M., Constantinoiu, S. M., & Ardeleanu, C. M. (2014) · PubMed Central · Cited by 153
IL-1R–MyD88 signaling in keratinocyte transformation and carcinogenesis
Cataisson, C., Salcedo, R., Hakim, S., Moffitt, A. B., Wright, L. N., Yi, M., Stephens, R. M., Dai, R., Lyakh, L. A., Schenten, D., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20101355 · Cited by 116
A mouse model for Costello syndrome reveals an Ang II–mediated hypertensive condition
Schuhmacher, A. J., Guerra, C. E., Sauzeau, V., Cañamero, M., Bustelo, X. R., & Barbacid, M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34385 · Cited by 128
Keratinocytic epidermal nevi are associated with mosaic RAS mutations
Hafner, C. M., Toll, A., Gantner, S., Mauerer, A., Lurkin, I., Acquadro, F., Fernández-Casado, A., Zwarthoff, E. C., Dietmaier, W., Baselga, E., et al. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2011-100637 · Cited by 119
Mosaic Activating Mutations in FGFR1 Cause Encephalocraniocutaneous Lipomatosis
Bennett, J. T., Tan, T. Y., Alcantara, D., Tétreault, M., Timms, A. E., Jensen, D. M., Collins, S., Nowaczyk, M. J. M., Lindhurst, M. J., Christensen, K. M., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.02.006 · Cited by 115
Preclinical efficacy of MEK inhibition in Nras-mutant AML
Burgess, M. R., Hwang, E., Firestone, A. J., Huang, T. Q., Xu, J., Zuber, J. A., Bohin, N., Wen, T., Kogan, S. C., Haigis, K. M., et al. (2014) · Blood · doi:10.1182/blood-2014-05-574582 · Cited by 118
Self-citationGenetic pathways, prevention, and treatment of sporadic colorectal cancer
Mundade, R., Imperiale, T. F., Prabhu, L., Loehrer, P. J., & Lu, T. (2014) · Oncoscience · doi:10.18632/oncoscience.59 · Cited by 109
Tothill, R. W., Li, J., Mileshkin, L., Doig, K., Siganakis, T., Cowin, P. A., FELLOWES, A. P., Semple, T. J., Fox, S. B., Byron, K. A., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4251 · Cited by 113
Racial Differences in BRAF / KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients
Yoon, H. H., Shi, Q., Alberts, S. R., Goldberg, R. M., Thibodeau, S. N., Sargent, D. J., & Sinicrope, F. A. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv186 · Cited by 114
Jaiswal, B. S., Janakiraman, V., Kljavin, N. M., Eastham‐Anderson, J., Cupp, J. E., Liang, Y., Davis, D. P., Hoeflich, K. P., & Seshagiri, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005717 · Cited by 120
Deng, Y., Nagae, G., Midorikawa, Y., Yagi, K., Tsutsumi, S., Yamamoto, S., Hasegawa, K., Kokudo, N., Aburatani, H., & Kaneda, A. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01549.x · Cited by 113
Yeh, C., Li, A., Chuang, J.-Z., Saito, M., Cáceres, A., & Sung, C.-H. (2013) · Developmental Cell · doi:10.1016/j.devcel.2013.07.014 · Cited by 107
Metadata
- Authors
- Schubbert, S., Shannon, K., & Bollag, G.
- Affiliations
- University of California, San Francisco (US)
- Plexxikon (United States) (US)
- Corresponding author
- Bollag, Gideon
- Venue
- Nature Reviews Cancer
- Published
- 2007-04
- Volume
- 7
- Issue
- 4
- Pages
- 295-308
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2088293068
- Cited by
- 1,583
- References
- 150
- Citations by year
- 2026: 24 · 2025: 30 · 2024: 47 · 2023: 61 · 2022: 46 · 2021: 68 · 2020: 59 · 2019: 64 · 2018: 75 · 2017: 84 · 2016: 102 · 2015: 101 · 2014: 150 · 2013: 141 · 2012: 116
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- Ras signaling, germline mutations, Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome, MEK/ERK signaling, Raf, developmental disorders, carcinogenesis, gain-of-function mutations, MAPK signaling
- MeSH terms
- Developmental Disabilities, Child, Preschool, Gene Expression Regulation, Humans, Models, Molecular, Neoplasms, Genes, ras, Signal Transduction, Protein Tyrosine Phosphatases, Germ-Line Mutation, Proto-Oncogene Proteins c-raf, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, Intracellular Signaling Peptides and Proteins, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Protein Tyrosine Phosphatase, Non-Receptor Type 11
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.